Abstract: The present invention relates to the field of probiotics, more particularly to the probiotic yeast Saccharomyces boulardii. The present invention provides genetic engineering approaches such as the use of gene deletions and the use of chimeric gene constructs to develop yeast strains with enhanced production of acetic acid. In addition, the invention also relates to the use of such yeast strains for the production of dietary supplements or pharmaceutical compositions to improve gastrointestinal comfort.

Abstract: The present invention relates to the field of fermentation and in particular to methods of improving the flavour and quality of beer produced by fermentation.

Abstract: Described herein are probiotics, more particularly [to] the probiotic yeast Saccharomyces boulardii. Even more particularly described herein are enhanced probiotic potency S. boulardii. Also described here are mutant alleles useful to develop yeast strains with enhanced production of acetic acid. In addition, described here is the use of such yeast strains for the production of dietary supplements or pharmaceutical compositions to improve gastrointestinal comfort.

Abstract: The present invention relates to inhibitors of hexokinase-dependent glucose carrier-mediated glucose uptake (Warbicins) that can be used to inhibit proliferation of cancer cells and other cells with an overactive glucose uptake and catabolism, i.e. the Warburg effect. The Warbicins of the invention are used in the prevention or treatment of cancers or other conditions associated with or aggravated by an overactive glycolytic flux, such as pulmonary hypertension, cardiac hypertrophy, heart failure, atherosclerosis, Alzheimer's diseases, multiple sclerosis, polycystic kidney disease, tuberculosis, diabetic kidney disease and autoimmune diseases.

Abstract: The invention relates to the field of microbiology, more particularly to fermentation technology. Yeast fermentation, particularly production of bio-based compounds starting from second generation carbon sources is often hampered by the presence of inhibitory chemicals. This application provides means and methods to overcome the negative effect of fermentation inhibitors, more particularly by providing chimeric genes and yeast strains comprising them that are tolerant to these inhibitors.

Abstract: The present invention relates to novel nucleic acid sequences encoding bacterial xylose isomerases that upon transformation of a eukaryotic microbial host cell, such as yeast, to confer to the host cell the ability of isomerising xylose to xylulose. The nucleic acid sequences encode xylose isomerases that originate from bacteria such as Eubacterium sp., Clostridium cellulosi and others. The invention further relates to fermentation processes wherein the transformed host cells ferment a xylose-containing medium to produce ethanol or other fermentation products.

Abstract: The present invention relates to the field of probiotics, more particularly to the probiotic yeast Saccharomyces boulardii. Even more particularly the present invention relates to enhanced probiotic potency of S. boulardii. The present invention provides mutant alleles useful to develop yeast strains with enhanced production of acetic acid. In addition, the invention also relates to the use of such yeast strains for the production of dietary supplements or pharmaceutical compositions to improve gastrointestinal comfort.

Abstract: The invention relates to the use of inulinase for reducing FODMAP (Fermentable oligo-, di-, monosaccharides and polyols) content in wholemeal bread or whole-meal dough. The invention further relates to wholemeal yeast fermented bread with a FODMAP content of maximum 0.2 gram fructans per 50 g of bread on dry matter base. The invention relates to methods of preparing a wholemeal yeast fermented bread with reduced FODMAP content, comprising the steps of mixing wholemeal and inulinase into a dough, allowing the dough to ferment and baking the dough. The invention further relates to methods of preparing a wholemeal dough with reduced FODMAP content in a wholemeal dough, comprising the steps of mixing wholemeal and inulinase into a dough, allowing the dough to ferment. Yeasts such as Kluyveromyces marxianus can be used as source of inulinase.

Abstract: The present invention relates to genes conferring acetic acid tolerance in yeast. More specifically, the invention relates to the use of DOT5, preferably in combination with CUP2 and/or HAA1 to obtain acid tolerance in yeast. Even more preferably, the invention relates to specific alleles of said genes, and to yeast strains comprising said specific alleles.

Abstract: The present invention relates to novel nucleic acid sequences encoding bacterial xylose isomerases that upon transformation of a eukaryotic microbial host cell, such as yeast, to confer to the host cell the ability of isomerising xylose to xylulose. The nucleic acid sequences encode xylose isomerases that originate from bacteria such as Eubacterium sp., Clostridium cellulosi and others. The invention further relates to fermentation processes wherein the transformed host cells ferment a xylose-containing medium to produce ethanol or other fermentation products.

Abstract: The disclosure relates to a specific yeast allele of KIN3 that is involved in maximal alcohol accumulation and/or in tolerance to high alcohol levels. Preferably, the alcohol is ethanol. In a preferred embodiment, this specific allele is combined with specific alleles of ADE1 and/or VPS70. More specifically, the disclosure relates to the use of these alleles for the construction and/or selection of high alcohol tolerant yeasts, by stacking of positive alleles, or the selection and construction of low alcohol producing yeasts by stacking of negative alleles.

Abstract: The present disclosure relates to the identification of a QTL associated with high ethanol tolerance in Saccharomyces spp. More specifically, it relates to specific alleles of MKT1 and APJ1 possibly combined with a specific allele of SWS2 that are important in obtaining a high ethanol tolerance in Saccharomyces spp. It relates further to the use of such alleles in the construction of high ethanol tolerant strains, and the use of these alleles in screening for ethanol tolerance.

Abstract: The disclosure relates to the use of a mutant SSK1 gene encoding a truncated ssk1 protein for the construction of a mutant yeast strain with decreased glycerol production, when compared to the wild-type strain. It relates further to the use of such strains for high-yield bioethanol production, especially in high osmotic media, or on cellulosic hydrolysates, where normal yeast strains do produce a significant amount of glycerol.

Abstract: The present invention relates to genes conferring acetic acid tolerance in yeast. More specifically, the invention relates to the use of DOT5, preferably in combination with CUP2 and/or HAA1 to obtain acid tolerance in yeast. Even more preferably, the invention relates to specific alleles of said genes, and to yeast strains comprising said specific alleles.

Abstract: The present invention relates to a mutant NNK1 allele, especially a mutant carrying a mutation at position of amino acid 807 of the wild type sequence. The invention relates further to the use of said mutant allele to increase the fermentation rate in yeast, preferably in Saccharomyces. The mutant allele is especially useful to increase the xylose to ethanol fermentation rate.

Abstract: The present invention relates to the use of GLO1 to modulate acetic acid tolerance in yeast. More specifically, it relates to the use of a specific GLO1 allele to confer tolerance to acetic acid, and to improve the fermentation performance of yeast in the presence of acetic acid.

Abstract: The present invention relates to recombinant microorganisms comprising an isobutanol producing metabolic pathway and methods of using said recombinant microorganisms to produce isobutanol. In various aspects of the invention, the recombinant microorganisms may comprise one or more modifications resulting in the reduction in the expression and/or activity of an endogenous transporter protein. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.

Abstract: The present invention relates to a mutant NNK1 allele, especially a mutant carrying a mutation at position of amino acid 807 of the wild type sequence. The invention relates further to the use of said mutant allele to increase the fermentation rate in yeast, preferably in Saccharomyces. The mutant allele is especially useful to increase the xylose to ethanol fermentation rate.

Abstract: The present disclosure relates to the identification of a QTL associated with high ethanol tolerance in Saccharomyces spp. More specifically, it relates to specific alleles of MKT1 and APJ1 possibly combined with a specific allele of SWS2 that are important in obtaining a high ethanol tolerance in Saccharomyces spp. It relates further to the use of such alleles in the construction of high ethanol tolerant strains, and the use of these alleles in screening for ethanol tolerance.

Abstract: The present invention relates to recombinant microorganisms comprising an isobutanol producing metabolic pathway and methods of using said recombinant microorganisms to produce isobutanol. In various aspects of the invention, the recombinant microorganisms may comprise one or more modifications resulting in the reduction in the expression and/or activity of an endogenous transporter protein. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.